We are monitoring the impact of COVID-19 on Europe Overactive Bladder Treatment Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 7584
Share on
Share on

Europe Overactive Bladder Treatment Market Research Report - Segmented By Treatment, By Disease And By Country(UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2019-2024)

Pulished: February, 2020
ID: 7584
Pages: 145

Europe Overactive Bladder Treatment Market Size & Growth (2019 - 2024)

As per the research report, the size of the Europe Overactive Bladder Treatment Market is valued at USD 0.93 billion in 2019 and is projected to grow at a CAGR of 3.2%, to reach USD 1.08 billion by 2024 during the forecast 2019-2024.

Overactive bladder is the condition in which the person has an urge to urinate frequently. Over time, this might lead to the loss of bladder control and this condition is called urge incontinence. People generally neglect this condition for years before it becomes a severe inconvenience.

The actual causes of this condition are not known. Initial treatment of this condition generally includes bladder training, pelvic floor exercises and behavioral methods. Medications and neurostimulations are recommended if other methods do not work. Also, there are procedures that use medical devices such as Urgent PC Neuromodulation System, injectables and surgical interventions are used for people with neurological conditions.

Due to the increasing number of people with neurological diseases, especially among the geriatric population, the demand for overactive bladder treatment has increased. The availability of innovative therapies and increasing pharmaceutical companies are driving the market growth. However, lack of awareness about the condition as well as the treatments available and side effects associated with the usage of drugs are hindering the market growth.

This research report segmented and sub-segmented into the following categories:

  • By Treatment: Mirabegron, Anticholinergics, Botox, Intravesical Instillation And Neurostimulation
  • By Disease: Neurogenic Overactive Bladder, Idiopathic Overactive Bladder
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

On the basis of region, the Europe Overactive Bladder Treatment market is segmented into N UK, Spain, Italy, Germany, and France. Europe region has the second-highest market share next only to North America and is expected to retain this position during the forecast period.

Key players operating in the Europe Overactive Bladder Treatment Market profiled in this report are Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International.

1. Introduction       

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods

                1.4 General Study Assumptions                

2. Research Methodology                 

                2.1 Introduction     

                2.2 Research Phases                      

      2.2.1 Secondary Research           

      2.2.2 Primary Research 

      2.2.3 Econometric Modelling      

      2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline

3. Overview             

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

                4.1 Market Drivers

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market    

5. Market Segmentation                    

                5.1 Treatment                  

      5.1.1 Introduction           

      5.1.2 Mirabegron            

      5.1.3 Anticholinergics    

                      5.1.3.1 Solifenacin

                      5.1.3.2 Fesoterodine

                      5.1.3.3 Tolterodine

                      5.1.3.4 Oxybutynin

                      5.1.3.5 Darifenacin

                      5.1.3.6 Trospium

                      5.1.3.7 Other Anticholinergics

      5.1.4 Botox        

      5.1.5 Intravesical Instillation       

      5.1.6 Neurostimulation 

      5.1.7 Y-o-Y Growth Analysis, By Treatment          

      5.1.8 Market Attractiveness Analysis, By Treatment        

      5.1.9 Market Share Analysis, By Treatment         

                5.2 Disease                        

      5.2.1 Introduction           

      5.2.2 Neurogenic Overactive Bladder     

                      5.2.2.1 Stroke

                      5.2.2.2 Spinal Cord Injury

                      5.2.2.3 Parkinson's disease

                      5.2.2.4 Multiple Sclerosis

                      5.2.2.5 Other Disorders

      5.2.3 Idiopathic Overactive Bladder         

      5.2.4 Y-o-Y Growth Analysis, By Disease                

      5.2.5 Market Attractiveness Analysis, By Disease              

      5.2.6 Market Share Analysis, By Disease               

6. Geographical Analysis                    

                6.1 Introduction     

      6.1.1 Regional Trends    

      6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                      6.1.3.1 By Geographical Area

                      6.1.3.2 By Treatment

                      6.1.3.3 By Disease

      6.1.4  Market Attractiveness Analysis     

                      6.1.4.1 By Geographical Area

                      6.1.4.2 By Treatment

                      6.1.4.3 By Disease

      6.1.5  Market Share Analysis      

                      6.1.5.1 By Geographical Area

                      6.1.5.2 By Treatment

                      6.1.5.3 By Disease

                6.2 U.K                 

                6.3 Spain   

                6.4 Germany                     

                6.5 Italy     

                6.6 France

7. Strategic Analysis             

                7.1 PESTLE analysis                         

      7.1.1 Political     

      7.1.2 Economic 

      7.1.3 Social         

      7.1.4 Technological         

      7.1.5 Legal          

      7.1.6 Environmental       

                7.2 Porter’s Five analysis    

      7.2.1 Bargaining Power of Suppliers        

      7.2.2 Bargaining Power of Consumers    

      7.2.3 Threat of New Entrants     

      7.2.4 Threat of Substitute Products and Services              

      7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis              

                8.1 Pfizer  

      8.1.1 Overview 

      8.1.2 Product Analysis   

      8.1.3 Financial analysis  

      8.1.4 Recent Developments       

      8.1.5 SWOT analysis       

      8.1.6 Analyst View          

                8.2 Allergan Plc                 

                8.3 Hisamitsu Pharmaceutical                    

                8.4 Johnson & Johnson                 

                8.5 Astellas Pharma Inc                 

                8.6 Teva Pharmaceutical Industries                         

                8.7 Mylan N.V                   

                8.8 Sanofi 

                8.9 Aurobindo Pharma Ltd

                8.10 Endo International                

9. Competitive Landscape                 

                9.1 Market share analysis  

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities               

Appendix                 

                a) List of Tables                

                b) List of Figures    

  • Regional  and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by disease with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Overactive Bladder Treatment Market By Treatment, From 2019-2024 ( USD Billion )
  2. Europe Mirabegron Market By Region, From 2019-2024 ( USD Billion )
  3. Europe Anticholinergics Market By Region, From 2019-2024 ( USD Billion )
  4. Europe Botox Market By Region, From 2019-2024 ( USD Billion )
  5. Europe Intravesical Instillation Market By Region, From 2019-2024 ( USD Billion )
  6. Europe Neurostimulation Market By Region, From 2019-2024 ( USD Billion )
  7. Europe Overactive Bladder Treatment Market By Disease, From 2019-2024 ( USD Billion )
  8. Europe Neurogenic Overactive Bladder Market By Region, From 2019-2024 ( USD Billion )
  9. Europe Idiopathic Overactive Bladder Market By Region, From 2019-2024 ( USD Billion )
  10. U.K. Overactive Bladder Treatment Market By Treatment, From 2019-2024 ( USD Billion )
  11. U.K. Overactive Bladder Treatment Market By Disease, From 2019-2024 ( USD Billion )
  12. Germany Overactive Bladder Treatment Market By Treatment, From 2019-2024 ( USD Billion )
  13. Germany Overactive Bladder Treatment Market By Disease, From 2019-2024 ( USD Billion )
  14. France Overactive Bladder Treatment Market By Treatment, From 2019-2024 ( USD Billion )
  15. France Overactive Bladder Treatment Market By Disease, From 2019-2024 ( USD Billion )
  16. Italy Overactive Bladder Treatment Market By Treatment, From 2019-2024 ( USD Billion )
  17. Italy Overactive Bladder Treatment Market By Disease, From 2019-2024 ( USD Billion )
  18. Spain Overactive Bladder Treatment Market By Treatment, From 2019-2024 ( USD Billion )
  19. Spain Overactive Bladder Treatment Market By Disease, From 2019-2024 ( USD Billion )
  20. Europe Overactive Bladder Treatment Market By Anticholinergics, From 2019-2024 ( USD Billion )
  21. Europe Solifenacin Market By Region, From 2019-2024 ( USD Billion )
  22. Europe Fesoterodine Market By Region, From 2019-2024 ( USD Billion )
  23. Europe Tolterodine Market By Region, From 2019-2024 ( USD Billion )
  24. Europe Oxybutynin Market By Region, From 2019-2024 ( USD Billion )
  25. Europe Darifenacin Market By Region, From 2019-2024 ( USD Billion )
  26. Europe Trospium  Market By Region, From 2019-2024 ( USD Billion )
  27. Europe Other Anticholinergics Market By Region, From 2019-2024 ( USD Billion )
  28. U.K. Overactive Bladder Treatment Market By Anticholinergics, From 2019-2024 ( USD Billion )
  29. Germany Overactive Bladder Treatment Market By Anticholinergics, From 2019-2024 ( USD Billion )
  30. France Overactive Bladder Treatment Market By Anticholinergics, From 2019-2024 ( USD Billion )
  31. Italy Overactive Bladder Treatment Market By Anticholinergics, From 2019-2024 ( USD Billion )
  32. Spain Overactive Bladder Treatment Market By Anticholinergics, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample